The Acute Respiratory Distress Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acute Respiratory Distress Syndrome. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued products.

GlobalData tracks 119 drugs in development for Acute Respiratory Distress Syndrome by 110 companies/universities/institutes. The top development phase for Acute Respiratory Distress Syndrome is preclinical with 64 drugs in that stage. The Acute Respiratory Distress Syndrome pipeline has 117 drugs in development by companies and two by universities/ institutes. Some of the companies in the Acute Respiratory Distress Syndrome pipeline products market are: BioStem Technologies, Pantherna Therapeutics and Suzhou Regend Therapeutics.

The key targets in the Acute Respiratory Distress Syndrome pipeline products market include T Cell Differentiation Antigen CD6 (T12 or TP120 or CD6), Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2), and Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1).

The key mechanisms of action in the Acute Respiratory Distress Syndrome pipeline product include T Cell Differentiation Antigen CD6 (T12 or TP120 or CD6) Inhibitor with two drugs in Phase II. The Acute Respiratory Distress Syndrome pipeline products include 15 routes of administration with the top ROA being Intravenous and 16 key molecule types in the Acute Respiratory Distress Syndrome pipeline products market including Small Molecule, and Cell Therapy.

Acute Respiratory Distress Syndrome overview

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia, and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure, confusion, and extreme tiredness.

For a complete picture of Acute Respiratory Distress Syndrome’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.